deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT01683656

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Sponsor: Calmy Alexandra

Conditions Atherosclerosis HIV
Interventions Placebo niacin/laropiprant
Updated 7 times since 2017 Last updated: Oct 7, 2019 Started: Aug 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Withdrawal of IMP from the market. Data on risk-benefit ratio pending.

Other Atherosclerosis trials with similar outcome

Browse all Atherosclerosis trials

Listed as NCT01683656, this PHASE4 trial focuses on Atherosclerosis and HIV and remains terminated or withdrawn. Sponsored by Calmy Alexandra, it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshotTerminated~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Nov 2019 — Jan 2021 [monthly]

    Terminated PHASE4

▶ Show 2 earlier versions

  1. Jun 2018 — Nov 2019 [monthly]

    Terminated PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE4

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calmy Alexandra
  • Fondation Ernest Boninchi
  • Swiss Heart Foundation
  • Swiss National Science Foundation
  • University Hospital, Geneva
Data source: University Hospital, Geneva

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations